Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an MIR
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • AAN 2025

American Academy of Neurology: (AAN 2025)
77th Annual Meeting

April 5 - 9, 2025

  1. All
  2. gMG
  3. Health Equity
  4. NMOSD

PDF

Assessment of hospitalizations in patients with generalized myasthenia gravis (gMG) before and during treatment with ravulizumab: results from a global registry

PDF

The phase 3 PREVAIL study assessing the efficacy and safety of subcutaneous gefurulimab in adults with generalized myasthenia gravis: trial in progress

PDF

Ravulizumab in patients with generalized myasthenia gravis from Japan: real-world outcomes

PDF

Long-term effectiveness and safety of eculizumab in patients with generalized myasthenia gravis real-world data from Japan

HTML

Characteristics of cohort with generalized myasthenia gravis in PREDICT study

HTML

Tracking daily impact of generalized myasthenia gravis using smartphone-based digital biomarkers: lessons learned from a 1-year study with ME&MGopen

PDF

The path to diagnosis and treatment among patients with generalized myasthenia gravis (gMG): health disparities experienced by racial and ethnic minorities from project ASPIRE (eliminAte diSparities and Promote equIty in Rare diseasE)

PDF

Evaluation of the indirect and nonmedical impacts of generalized myasthenia gravis on patients and caregivers

PDF

A phase 3, open-label, single-arm, multicenter study to evaluate ravulizumab administered intravenously in pediatric patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

PDF

Change in concomitant immunosuppressive therapies for generalized myasthenia gravis in patients receiving complement C5 inhibitor therapies: a retrospective analysis of registry data

PDF

Effectiveness and safety of ravulizumab in generalized myasthenia gravis: updated analysis from a global registry

PDF

Outcomes for patients with gMG prescribed ravulizumab or efgartigimod treatment: A retrospective medical record analysis

PDF

The REthinking MeAsures of DivErsity (REMADE) study: developing new diversity measures to ensure fair representation in clinical trials

PDF

Patient preferences for treatment features in neuromyelitis optica spectrum disorder (NMOSD): results from a discrete choice experiment

PDF

Efficacy and safety of ravulizumab in adults with AQP4-Ab+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial

HTML

ACT with NMOSD – a targeted, telehealth-delivered mental health intervention for NMOSD patients & caregivers

PDF

The total economic impact of anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) on patients and caregivers in the United States

PDF

NMO SPOTLIGHT Registry: real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD)

PDF

Clinical characteristics associated with high baseline glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in patients with anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) from the PREVENT and CHAMPION-NMOSD trials

PDF

Time to vaccination after rituximab (RTX) discontinuation in patients with anti–aquaporin–4 antibody–positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD): a post-hoc analysis of the CHAMPION-NMOSD trial

HTML

Clinical and radiological outcomes in people with Aquaporin-4 Antibody positive neuromyelitis optica spectrum disorder following ravulizumab treatment (AMAZE)

PDF

Assessment of hospitalizations in patients with generalized myasthenia gravis (gMG) before and during treatment with ravulizumab: results from a global registry

PDF

The phase 3 PREVAIL study assessing the efficacy and safety of subcutaneous gefurulimab in adults with generalized myasthenia gravis: trial in progress

PDF

Ravulizumab in patients with generalized myasthenia gravis from Japan: real-world outcomes

PDF

Long-term effectiveness and safety of eculizumab in patients with generalized myasthenia gravis real-world data from Japan

HTML

Characteristics of cohort with generalized myasthenia gravis in PREDICT study

HTML

Tracking daily impact of generalized myasthenia gravis using smartphone-based digital biomarkers: lessons learned from a 1-year study with ME&MGopen

PDF

The path to diagnosis and treatment among patients with generalized myasthenia gravis (gMG): health disparities experienced by racial and ethnic minorities from project ASPIRE (eliminAte diSparities and Promote equIty in Rare diseasE)

PDF

Evaluation of the indirect and nonmedical impacts of generalized myasthenia gravis on patients and caregivers

PDF

A phase 3, open-label, single-arm, multicenter study to evaluate ravulizumab administered intravenously in pediatric patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

PDF

Change in concomitant immunosuppressive therapies for generalized myasthenia gravis in patients receiving complement C5 inhibitor therapies: a retrospective analysis of registry data

PDF

Effectiveness and safety of ravulizumab in generalized myasthenia gravis: updated analysis from a global registry

PDF

Outcomes for patients with gMG prescribed ravulizumab or efgartigimod treatment: A retrospective medical record analysis

PDF

The REthinking MeAsures of DivErsity (REMADE) study: developing new diversity measures to ensure fair representation in clinical trials

PDF

Patient preferences for treatment features in neuromyelitis optica spectrum disorder (NMOSD): results from a discrete choice experiment

PDF

Efficacy and safety of ravulizumab in adults with AQP4-Ab+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial

HTML

ACT with NMOSD – a targeted, telehealth-delivered mental health intervention for NMOSD patients & caregivers

PDF

The total economic impact of anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) on patients and caregivers in the United States

PDF

NMO SPOTLIGHT Registry: real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD)

PDF

Clinical characteristics associated with high baseline glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in patients with anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) from the PREVENT and CHAMPION-NMOSD trials

PDF

Time to vaccination after rituximab (RTX) discontinuation in patients with anti–aquaporin–4 antibody–positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD): a post-hoc analysis of the CHAMPION-NMOSD trial

HTML

Clinical and radiological outcomes in people with Aquaporin-4 Antibody positive neuromyelitis optica spectrum disorder following ravulizumab treatment (AMAZE)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 3/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data 
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States